The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy. Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Overall Survival (OS)
Timeframe: From the date of esophagectomy to death or last follow-up, up to 73 months.